Signal Transduction and Targeted Therapy (ISSN 2059-3635 (online), ISSN 2095-9907 (print), CN 51-1758/R) is an open access journal, which aims to accomplish timely publication of the latest discoveries and progress in both basic science and clinical research related to signal transduction and targeted therapy. It will include research on major human diseases, such as cancer, autoimmune disorders and others.
Signal Transduction and Targeted Therapy is a multidisciplinary journal, covering topics including but not limited to molecular biology, cell biology, pharmacology, medicinal chemistry, computational chemistry, systems biology, bioinformatics, and clinical medicine.
The editorial team of Signal Transduction and Targeted Therapy is composed of a highly respected editorial board of researchers from across the globe, led by the internationally renowned Professor Carlo M. Croce, together with Professor Kang Zhang and Professor Yu-Quan Wei.
This journal is now indexed in Science Citation Index Expanded (SCIE), Journal Citation Reports/Science Edition, BIOSIS previews, Directory of Open Access Journals (DOAJ), MEDLINE, PubMed Central (PMC) and Scopus.
Article metrics such as number of downloads, citations and online attention are available from each article page, and provide an overview of the attention received by a paper.
The 2020 journal metrics for Signal Transduction and Targeted Therapy are as follows:
2 Year Impact Factor: 18.187*
5 Year Impact Factor: 21.177*
JCR Rank*: 5/298(Q1) BIOCHEMISTRY & MOLECULAR BIOLOGY, 11/195(Q1) CELL BIOLOGY
Immediacy Index: 7.657*
Eigenfactor Score: 0.00573*
Article Influence Score: 4.284*
Journal Citation Indicator: 1.85*
Total webpage views, 2020: 1,451,092
Total successful full-text article requests, 2020: 1,589,509
Number of days from Submission to acceptance: 104 days
Number of days from acceptances at publisher to published online: 27 days
*2020 Journal Citation Reports (Clarivate Analytics, 2021)
The editorial policies of this publication are determined jointly by its Editorial Board and Springer Nature in accordance with the legal and regulatory requirements of China.